A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma.

Dave SinghRainard FuhrNicholas P BirdSarah MoleKelly HardesYau Lun ManAnthony CahnSteven W YanceyIsabelle J Pouliquen

Published in: British journal of clinical pharmacology (2021)

GSK3511294 was well tolerated, with linear and dose proportional PK, extended half-life and blood eosinophil count reduction, supporting less frequent dosing versus other anti-IL-5 mAbs.

Keyphrases

monoclonal antibody
signaling pathway
pi k akt
chronic obstructive pulmonary disease
open label
lung function
clinical trial
air pollution
cell proliferation
cystic fibrosis
placebo controlled